BioStem Technologyes, Inc. (BSEM) sees shares rise from $1 to over $9 and there may be no end in sight…

There are plenty of reasons why this growing biotech company should be on your watchlist There are plenty of reasons why this growing biotech company should be on your watchlist                                                                                                      Editor’s Note: When we see offers from other publishers that might interest you, we pass them along. Below you’ll find one from our friends at Huge Alerts. Please note that their opinions may differ from what you read in Behind the Markets. You are receiving this email because you are subscribed to Behind the Markets. If you no longer wish to receive these partner emails, please [unsubscribe]( here. --------------------------------------------------------------- BioStem Technologyes, Inc. (BSEM) sees shares rise from $1 to over $9 and there may be no end in sight… [bsem 2]( Catalysts are piling up for this fast-growing biotech company which may be one of the biggest biotech darlings in the making. As regenerative medicine continues to find its way into the mainstream, emerging biotech company [BioStem Technologies, Inc. (OTC: BSEM)]( is making waves for its focus on harnessing elements of perinatal tissue derived from the human placenta for manufacturing structural tissue allografts to heal wounds. This includes a curated suite of versatile products called Vendaje. The company has been capturing Wall Street’s attention as its share price has risen from around $1 in July of 2023 to as high as $7.00 by year-end. [This year share prices have exceeded $9!]( One of the most exciting catalysts for potential growth comes from a recent price target increase from notable research firm Zack’s Small Cap Research. It comes shortly after the company released preliminary and unaudited numbers that showed net revenue for 4Q2023 of $11.5 million, a [more than 1300% increase from the year ago period!]( It wasn’t that long ago that BioStem Technologies, Inc. (OTC: BSEM) was given a $9.25 price target from Zack’s Small Cap research. [Today that price target is at $18.70!]( The firm has written that “Investors are starting to agree with our view as the stock has moved solidly higher over the past year, moving up over 140%, while the Russell 2000 was roughly flat over the same period. The company really gained momentum in the second half of 2023 as BioStem was awarded a valuable Q code for Vendaje AC by the Centers for Medicare and Medicaid Services and solidified its funding situation. Recently, the company announced that its Healthcare Common Procedure Coding System code for Vendaje AC became effective and that the Center for Medicare Services established national pricing for AmnioWrap2 in all 50 states and territories.” Zack’s Small Cap Research believes that BioStem has a solid foothold in that tough to break into community and the acceptance and use of the company’s products will continue to accelerate. [Discover why there could be further upside ahead for BioStem Technologies in 2024!]( Our mailing address is: Behind the Markets, LLC 4260 NW 1st Avenue, Suite 55 Boca Raton, FL 33431 We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security. We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of BioStem Technologies, Inc. (BSEM). The compensation consists of $2,000 was received/will be received from Sideways Frequency. This compensation should not be considered as an endorsement of the securities of adviser BioStem Technologies, Inc. (BSEM) and we are not responsible for any errors or omissions in any information provided about the securities of BioStem Technologies, Inc. (BSEM). We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions. This disclosure is made as of 3/4/24. Copyright © 2024 Behind the Markets, LLC, All rights reserved. You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our [Privacy Policy]( or our [Legal Notices.]( [Unsubscribe](